SuperGen Selected to be Included in NASDAQ Biotechnology Index DUBLIN, Calif., Nov. 17 /PRNewswire-FirstCall/ -- SuperGen, Inc. announced today that it will be included in the NASDAQ Biotechnology Index, effective at the opening of the stock market on November 24, 2003. All securities in the Biotechnology Index are classified as either 'biotechnology' or 'pharmaceutical' according to the FTSE Global Classification System(TM). In addition, each security must be listed on the NASDAQ National Market and meet requirements for market value, average daily share volume and seasoning as a public company. Companies are added to or removed from the Index on a semi-annual basis in May and November. Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of anticancer products. The Company's website can be reached at http://www.supergen.com/. Contact: Tim Enns, Vice President, Investor Relations & Business Development, SuperGen Inc., 800-353-1075, ext. 111 DATASOURCE: SuperGen, Inc. CONTACT: Tim Enns, Vice President, Investor Relations & Business Development, SuperGen Inc., +1-800-353-1075, ext. 111 Web site: http://www.supergen.com/

Copyright